OMBP Stock UPDATES Omni Bio Pharm Inc (OMBP) 0.2400 09/11/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Omni Bio Pharm Inc (OMBP) 0.2400 $OMBP

Omni Bio Appoints Jack Riccardi as Chief Financial Officer
Marketwire - Thu Aug 14, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio" , an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the appointment of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi's appointment will become effective on September 1, 2014.

Omni Bio Pharmaceutical Inc appoints Sandra J. Wrobel to board
M2 - Thu Jul 18, 6:31AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical Inc (OTCBB:OMBP) reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013.

Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Marketwire - Wed Jul 17, 3:00PM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Ms. Sandra J. Wrobel, MBA, to its Board of Directors, effective July 15, 2013.

Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Marketwire - Wed Jul 10, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow transplantation, commonly referred to as Graft versus Host Disease ("GvHD" .

Omni Bio Announces First Results for Its Lead Recombinant Molecule
Marketwire - Fri Mar 15, 7:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT.

Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
Marketwire - Wed Feb 06, 8:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Michael E. Kamarck, Ph.D., to its Board of Directors, effective January 31, 2013.

Omni Bio Pharmaceutical CEO Provides Company Update
Marketwire - Thu Jan 31, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today provided a company update from its new CEO, Dr. Bruce E. Schneider.

Omni Bio Pharmaceutical Appoints New CEO
Marketwire - Thu Dec 20, 7:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Canada and Ukraine Fortify Defense with UGV Partnership

Updated Category News Views 20

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

Continue Reading
Special Needs Group Partners with MAST to Enhance Accessibility

Updated Category News Views 29

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...

Continue Reading
Trial for Former OB/GYN Arthur Park Begins in Bakersfield

Updated Category News Views 12

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Continue Reading
Fluence Energy Faces Major Lawsuit Amid $3B Loss

Updated Category News Views 19

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Continue Reading
TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Updated Category News Views 31

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Continue Reading
AtWork Welcomes Franchise Vet Sarah Goehring

Updated Category News Views 20

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Continue Reading
Laars Welcomes Women in Manufacturing to Facility Tour

Updated Category News Views 14

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

Continue Reading
New Data on SKYRIZI Offers Hope for Crohn's Patients

Updated Category News Views 31

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Continue Reading
Dr. Anderson’s Journey: Leadership with Faith and Service

Updated Category News Views 8

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Continue Reading
Franco-Nevada's Q3 Results Loom: Investors Ready

Updated Category News Views 28

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding EREVs: A Pathway to Successful Electrification

Updated Category News Views 195

Understanding EREVs and Their Role in Electrification As the automotive landscape evolves, consumers find themselves at a crossroads, uncertain about the transition to fully battery electric vehicles (BEVs). In this environment, Extended Range Electric Vehicles (EREVs) emerge as a practical alternative, catering to new-car buyers seeking a balance between traditional...

Continue Reading
Dry Chemistry Analyzer Market Expected to Hit USD 33.2 Billion

Updated Category News Views 154

Overview of the Dry Chemistry Analyzer Market The global dry chemistry analyzer market has set a remarkable trajectory, starting with a valuation of USD 15.2 billion, and is projected to reach an impressive USD 33.2 billion in the upcoming years. This growth is fueled by the increasing necessity for effective diagnostic tools that enhance patient outcomes. These analyzers...

Continue Reading
iPower's Strategic Shift Towards Flexible Funding Solutions

Updated Category News Views 159

iPower's Strategic Move for Enhanced Capital Flexibility iPower Inc. (NASDAQ: IPW), a data-driven e-commerce retailer, is making proactive strides to improve its financial flexibility. The company is exploring diverse funding mechanisms to tailor its financial structure to current market dynamics, ultimately boosting liquidity. Transitioning to Non-Bank Financing...

Continue Reading
Netskope Strengthens Leadership with Wes Simons Appointment

Updated Category News Views 121

Netskope Welcomes Wes Simons as Senior Vice President Netskope has officially welcomed Wes Simons to its executive team as the Senior Vice President of North America Sales. This strategic appointment comes as the company seeks to boost its growth in a key market. With more than 25 years of experience in cybersecurity sales, Simons is poised to be a significant asset for...

Continue Reading
Understanding the Recent Rating Change for Nissan Global Reinsurance

Updated Category News Views 188

AM Best Adjusts Nissan Global Reinsurance's Credit Ratings AM Best recently announced a downgrade of the Financial Strength Rating for Nissan Global Reinsurance, Ltd. (NGRe), reducing it to A- (Excellent) from A (Excellent). Alongside this, the Long-Term Issuer Credit Rating has also been adjusted from "a" (Excellent) to "a-" (Excellent). Notably, the outlook for these...

Continue Reading